Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model

Hepatology

Volumn 55, Issue 1, 2012, Pages 141-152

  Avella, Diego M ^a   Li, Guangfu ^a   Schell, Todd D ^a   Liu, Dai ^a   Zhang, Samuel Shao Min ^a   Lou, Xi ^a   Berg, Arthur ^a   Kimchi, Eric T ^a   Tagaram, Hephzibah Rani S ^a   Yang, Qing ^a   Shereef, Serene ^a   Garcia, Luis S ^a   Kester, Mark ^a   Isom, Harriet C ^a   Rountree, C Bart ^a   Staveley O'Carroll, Kevin F ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANZYME B; PERFORIN; PROTEIN TAG; STAT3 PROTEIN; SUNITINIB; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL TRANSFER; COLONY FORMATION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; INTERFERON PRODUCTION; LIVER CELL CARCINOMA; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; THERAPY EFFECT; TUMOR VOLUME;

ADENOCARCINOMA; ADOPTIVE TRANSFER; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HEP G2 CELLS; HEPATOCYTES; HUMANS; IMMUNE TOLERANCE; IMMUNOCOMPETENCE; INDOLES; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PYRROLES; STAT3 TRANSCRIPTION FACTOR;

EID: 84155185190     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24652     Document Type: Article

References (31)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
2. Bujanda DA, Morales JA, Sarmiento UB, Grau SS, Franco CR. Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. Clin Transl Oncol 2009; 11: 604-608.
3. Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115-3120.
4. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807.
5. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Instit 2008; 100: 698-711.
6. Seliger B, Massa C, Rini B, Ko J, Finke J. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends Mol Med 2010; 16: 184-192.
7. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-896.
8. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69: 2506-2513.
9. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
10. Cheng A, Kang Y, Lin D, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). Paper presented at: ASCO Annual Meeting; June 3-7, 2011, 2011; Chicago, IL.
11. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007; 7: 645-58.
12. Luis Garcia PS, Diego Avella, Hepzibah Tagaram, Yixing Jiang, Serene Shereef. MTD2 mice provide an excellent model for in vivo adoptive transfer studies to evaluate the tumor antigen specific T cell response to hepatocellular. J Surg Res 2008; 144: 386.
13. Held WA, Mullins JJ, Kuhn NJ, Gallagher JF, Gu GD, Gross KW. T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein/SV40 T antigen hybrid gene. EMBO J 1989; 8: 183-191.
14. Tevethia SS, Greenfield RS, Flyer DC, Tevethia MJ. SV40 transplantation antigen: relationship to SV40-specific proteins. Cold Spring Harb Symp Quant Biol 1980; 44(Pt 1): 235-242.
15. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 95: 2509-2514.
16. Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP, et al. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol 2003; 171: 697-707.
17. Li G, Li W, Angelastro JM, Greene LA, Liu DX. Identification of a novel DNA binding site and a transcriptional target for activating transcription factor 5 in c6 glioma and mcf-7 breast cancer cells. Mol Cancer Res 2009; 7: 933-943.
18. Otahal P, Schell TD, Hutchinson SC, Knowles BB, Tevethia SS. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. J Immunol 2006; 177: 3089-3099.
19. Otahal P, Knowles BB, Tevethia SS, Schell TD. Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors. J Immunol 2007; 179: 6686-6695.
20. Schell TD, Knowles BB, Tevethia SS. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res 2000; 60: 3002-3012.
21. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005; 11: 595-596.
22. Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, Rodes J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. HEPATOLOGY 2007; 46: 1919-1926.
23. Seandel M, Shia J, Linkov I, Maki RG, Antonescu CR, Dupont J. The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. Clin Cancer Res 2006; 12: 6203-6204.
24. Huynh H, Ngo VC, Choo SP, Poon D, Koong HN, Thng CH, et al. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr Cancer Drug Targets 2009; 9: 738-747.
25. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004; 23: 5426-5434.
26. Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005; 42: 1208-1236.
27. Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 2009; 28: 961-972.
28. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10: 48-54.
29. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999; 10: 39-49.
30. Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, et al. A critical role for Stat3 signaling in immune tolerance. Immunity 2003; 19: 425-436.
31. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314-1321.